spacer
home > ebr > summer 2003 > smi conference london march 2003, biologics: overcoming the challenges of development and manufacture
PUBLICATIONS
European Biopharmaceutical Review

SMi Conference London March 2003, Biologics: Overcoming the Challenges of Development and Manufacture

The SMi conference was opened by Dr David Glover, Chief Medical Officer at Cambridge Antibody Technology, who outlined the key challenges for biologics manufacture today: the predicted shortage of manufacturing capacity, the decision to outsource or make in-house, and technical and regulatory challenges.

It is predicted that just 10 monoclonal antibody (mabs) products would consume 75 per cent of the worlds' biologic manufacturing capacity and yet there are 60 mabs likely to emerge onto the market in the next one to seven years. However, the estimate of 400 mabs in clinical trial, which is often quoted, is probably an overestimate, as a single mab can be in clinical trial for a number of different clinical indications. This reduces the current estimate from 400 to around 100. Whilst currently, 30 per cent of FDA drug applications are for biotech drugs, a curious statistic is that biologics produced by pharma/biotech alliances have a 70 per cent greater chance of receiving FDA approval. It is not known whether this is a synergistic effort of the companies working together or if biologic drugs are more likely to get FDA approval than chemical entity-based drugs.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Keith Chidwick, Consultant at Technomark Consulting Services Ltd
spacer
Keith Chidwick
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

3P Biopharmaceuticals receives FDA approval

[Pamplona, September 16th, 2019] 3P Biopharmaceuticals (3P), a leading Contract Development and Manufacturing Organisation (CDMO) specialized in process development and GMP manufacturing of biologics, receives FDA approval after completing the Pre-Approval Inspection (PAI) conducted at the 3P drug substance manufacturing facility.
More info >>

White Papers

Quality By Design

Biopharma Group

Quality by Design (QbD) is a systematic approach to development that begins with the defined objectives and emphasizes science and quality risk management in order to achieve those goals. QbD ensures that the quality of the product is built into production processes from the outset, rather than being tested after development has already commenced.
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement